Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells


"We are very pleased to have been awarded this patent," said Dr. Kenneth Carter, Ph.D, Executive Chairman of Neuralstem. "It provides Neuralstem with broad protection for the use of our neural stem cells in the treatment of diseases such as stroke, traumatic brain injury, spinal cord injury, and ALS, and extends the scope and lifespan of our neural stem cell IP portfolio."

About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. The Company has two lead development candidates:

- NSI-566 is a stem cell therapy being tested in clinical trials for treatment of paralysis due to ischemic stroke, amyotrophic lateral sclerosis (ALS), and chronic spinal cord injury (cSCI). Results from these trials have indicated that NSI-566 is safe and provided preliminary evidence of clinical benefit across all three indications.

- NSI-189 is a small molecule in clinical development for major depressive disorder and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, diabetic neuropathy, and stroke.

In February, 2019, the Company announced the initiation of efforts to identify preclinical and clinical stage assets that could be acquired and developed to expand its current pipeline of therapeutic products.

Cautionary Statement Regarding Forward Looking Information
This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Investor Contact:
Sunflower Life Sciences
josh@sunflowerlifesciences.com


SOURCE Neuralstem, Inc.